Susquehanna International Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-108,297
| Closed | -$200K | – | 13694 |
|
|
2023
Q1 | $200K | Buy |
108,297
+79,005
| +270% | +$97.9K | ﹤0.01% | 10587 |
|
|
2022
Q4 | $32.5K | Buy |
29,292
+7,025
| +32% | +$10K | ﹤0.01% | 11597 |
|
|
2022
Q3 | $52K | Sell |
22,267
-18,988
| -46% | -$67.2K | ﹤0.01% | 12182 |
|
|
2022
Q2 | $125K | Buy |
+41,255
| New | +$201K | ﹤0.01% | 11243 |
|
|
2021
Q3 | – | Sell |
-12,108
| Closed | -$75K | – | 13861 |
|
|
2021
Q2 | $82K | Sell |
12,108
-10,014
| -45% | -$83.2K | ﹤0.01% | 12173 |
|
|
2021
Q1 | $227K | Sell |
22,122
-3,806
| -15% | -$41.7K | ﹤0.01% | 11169 |
|
|
2020
Q4 | $181K | Buy |
25,928
+12,011
| +86% | +$93.5K | ﹤0.01% | 10116 |
|
|
2020
Q3 | $114K | Buy |
+13,917
| New | +$86.3K | ﹤0.01% | 9841 |
|
|
2020
Q1 | – | Sell |
-48,325
| Closed | -$278K | – | 11112 |
|
|
2019
Q4 | $422K | Buy |
48,325
+28,084
| +139% | +$152K | ﹤0.01% | 7312 |
|
|
2019
Q3 | $67K | Buy |
20,241
+3,917
| +24% | +$15.7K | ﹤0.01% | 9703 |
|
|
2019
Q2 | $81K | Sell |
16,324
-28,299
| -63% | -$150K | ﹤0.01% | 9698 |
|
|
2019
Q1 | $277K | Buy |
44,623
+18,915
| +74% | +$91.4K | ﹤0.01% | 7354 |
|
|
2018
Q4 | $87K | Sell |
25,708
-151,674
| -86% | -$709K | ﹤0.01% | 8280 |
|
|
2018
Q3 | $1.15M | Buy |
177,382
+126,570
| +249% | +$941K | ﹤0.01% | 4947 |
|
|
2018
Q2 | $389K | Sell |
50,812
-46,538
| -48% | -$671K | ﹤0.01% | 7330 |
|
|
2018
Q1 | $2.18M | Buy |
97,350
+84,531
| +659% | +$1.88M | ﹤0.01% | 3760 |
|
|
2017
Q4 | $163K | Buy |
+12,819
| New | +$188K | ﹤0.01% | 8434 |
|
Other funds holding JNCE
Susquehanna International Group's JNCE Position: Q2 2023 in Review
Susquehanna International Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 108,297 shares — an estimated $200K sold.
Susquehanna International Group first reported a position in JNCE in Q4 2017 and held it in 17 quarters. The position peaked at $2.18M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Susquehanna International Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 108,297 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $200K.
- Susquehanna International Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
- Susquehanna International Group's Jounce Therapeutics, Inc. Common Stock position peaked at $2.18M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.